B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets

Journal of Dermatology

Volumn 43, Issue 1, 2016, Pages 39-45

  Yoshizaki, Ayumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

autoimmunity; B lymphocyte; CD19; regulatory B cell; systemic sclerosis

Indexed keywords

B CELL ANTIGEN RECEPTOR; BLEOMYCIN; CD19 ANTIGEN; INTERLEUKIN 10; LYMPHOCYTE RECEPTOR; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN SPECIFICITY; APOPTOSIS; B CELL DEPLETION THERAPY; B CELL HOMEOSTASIS; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CELL INFILTRATION; DISEASE ASSOCIATION; EXPERIMENTAL ANIMAL; GENETIC MODEL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; REGULATORY B CELL; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; SCLERODERMA, SYSTEMIC;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE ACTIVATION; MICE; SCLERODERMA, SYSTEMIC;

EID: 84962433251     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13184     Document Type: Review

References (75)

1. LeRoy EC, Black C, Fleischmajer R, et al,. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
2. Furst DE, Clements PJ,. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol 1997; 24 (Suppl 48): 53-57.
3. Yoshizaki A, Yanaba K, Iwata Y, et al,. Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann Rheum Dis 2011; 70: 194-200.
4. Yoshizaki A, Komura K, Iwata Y, et al,. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009; 29: 180-189.
5. Okano Y,. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1996; 22: 709-735.
6. Sato S, Fujimoto M, Hasegawa M, et al,. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004; 41: 1123-1133.
7. Lipsky PE,. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
8. Whitfield ML, Finlay DR, Murray JI, et al,. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-12324.
9. Yoshizaki A, Miyagaki T, DiLillo DJ, et al,. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 2012; 491: 264-268.
10. Fillatreau S,. Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection. Immunol Rev 2011; 240: 52-71.
11. Mauri C,. Regulation of immunity and autoimmunity by B cells. Curr Opin Immunol 2010; 22: 761-767.
12. Chan OT, Hannum LG, Haberman AM, et al,. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-1648.
13. Shlomchik MJ, Craft JE, Mamula MJ,. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147-153.
14. Kouskoff V, Korganow AS, Duchatelle V, et al,. Organ-specific disease provoked by systemic autoimmunity. Cell 1996; 87: 811-822.
15. Korganow AS, Ji H, Mangialaio S, et al,. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999; 10: 451-461.
16. Matsumoto I, Staub A, Benoist C, et al,. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999; 286: 1732-1735.
17. Goodnow CC,. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996; 93: 2264-2271.
18. Tedder TF,. Introduction: response-regulators of B lymphocyte signaling thresholds provide a context for antigen receptor signal transduction. Semin Immunol 1998; 10: 259-265.
19. Tedder TF, Inaoki M, Sato S,. The CD19/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997; 6: 107-118.
20. Bolland S, Ravetch JV,. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000; 13: 277-285.
21. Majeti R, Xu Z, Parslow TG, et al,. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 2000; 103: 1059-1070.
22. Pan C, Baumgarth N, Parnes JR,. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity 1999; 11: 495-506.
23. Inaoki M, Sato S, Weintraub BC, et al,. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997; 186: 1923-1931.
24. Sato S, Ono N, Steeber DA, et al,. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 1996; 157: 4371-4378.
25. Sato S, Miller AS, Inaoki M, et al,. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996; 5: 551-562.
26. O'Keefe TL, Williams GT, Davies SL, et al,. Hyperresponsive B cells in CD22-deficient mice. Science 1996; 274: 798-801.
27. Tedder TF, Zhou L-J, Engel P,. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today 1994; 15: 437-442.
28. Engel P, Zhou L-J, Ord DC, et al,. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995; 3: 39-50.
29. Rickert RC, Rajewsky K, Roes J,. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995; 376: 352-355.
30. Sato S, Steeber DA, Tedder TF,. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci USA 1995; 92: 11558-11562.
31. Sato S, Steeber DA, Jansen PJ, et al,. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J Immunol 1997; 158: 4662-4669.
32. Zhou L-J, Smith HM, Waldschmidt TJ, et al,. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B lymphocyte development. Mol Cell Biol 1994; 14: 3884-3894.
33. Sato S, Hasegawa M, Fujimoto M, et al,. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165: 6635-6643.
34. Sato S, Fujimoto M, Hasegawa M, et al,. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918-1927.
35. Asano N, Fujimoto M, Yazawa N, et al,. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 2004; 165: 641-650.
36. Famularo G, Giacomelli R, Alesse E, et al,. Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 1989; 29: 59-63.
37. Fleischmajer R, Perlish JS, Reeves JRT,. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977; 20: 975-984.
38. Fujimoto M, Sato S,. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005; 17: 746-751.
39. Wang J, Watanabe T,. Expression and function of Fas during differentiation and activation of B cells. Int Rev Immunol 1999; 18: 367-379.
40. Siracusa LD, McGrath R, Ma Q, et al,. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996; 6: 300-313.
41. Saito S, Nishimura H, Phelps RG, et al,. Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene. Mol Med 2000; 6: 825-836.
42. Wallace VA, Kondo S, Kono T, et al,. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994; 24: 1463-1466.
43. Kodera T, McGaha TL, Phelps R, et al,. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-b production by fibroblasts. Proc Natl Acad Sci USA 2002; 99: 3800-3805.
44. Saito E, Fujimoto M, Hasegawa M, et al,. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-1462.
45. Hasegawa M, Fujimoto M, Takehara K, et al,. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J Dermatol Sci 2005; 39: 1-7.
46. Matsushita T, Fujimoto M, Hasegawa M, et al,. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol 2007; 127: 2772-2780.
47. Hasegawa M, Hamaguchi Y, Yanaba K, et al,. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006; 169: 954-966.
48. Arnett FC, Cho M, Chatterjee S, et al,. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001; 44: 1359-1362.
49. Yamamoto T, Takagawa S, Katayama I, et al,. Animal model of sclerotic skin. I: local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112: 456-462.
50. Yamamoto T,. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006; 297: 333-344.
51. Yoshizaki A, Iwata Y, Komura K, et al,. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008; 172: 1650-1663.
52. Rosen A, Casciola-Rosen L,. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
53. Casiano CA, Martin SJ, Green DR, et al,. Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 1996; 184: 765-770.
54. Sgonc R, Gruschwitz MS, Dietrich H, et al,. Endothelial cell apoptosis is a primary pathogeneic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-792.
55. Yamamoto T, Nishioka K,. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004; 122: 44-50.
56. Ogawa F, Shimizu K, Muroi E, et al,. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology 2006; 45: 815-818.
57. Simonini G, Pignone A, Generini S, et al,. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 2000; 155: 1-15.
58. Inghilleri S, Morbini P, Oggionni T, et al,. In situ assessment of oxidant and nitrogenic stress in bleomycin pulmonary fibrosis. Histochem Cell Biol 2006; 125: 661-669.
59. Manoury B, Nenan S, Leclerc O, et al,. The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir Res 2005; 6: 11-22.
60. Yoshizaki A, Yanaba K, Ogawa A, et al,. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum 2011; 63: 3086-3097.
61. Mendoza G, Alvarez AI, Pulido MM, et al,. Inhibitory effects of different antioxidants on hyaluronan depolymerization. Carbohydr Res 2007; 342: 96-102.
62. Janeway CA Jr, Medzhitov R,. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
63. Marshak-Rothstein A,. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-835.
64. Lotze MT, Tracey KJ,. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
65. Yoshizaki A, Iwata Y, Komura K, et al,. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol 2008; 35: 1825-1829.
66. Dumitriu IE, Baruah P, Manfredi AA, et al,. HMGB1: guiding immunity from within. Trends Immunol 2005; 26: 381-387.
67. Wang H, Bloom O, Zhang M, et al,. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
68. Yanaba K, Bouaziz JD, Matsushita T, et al,. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223: 284-299.
69. Matsushita T, Yanaba K, Bouaziz JD, et al,. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-3430.
70. Bouaziz JD, Yanaba K, Tedder TF,. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224: 201-214.
71. DiLillo DJ, Matsushita T, Tedder TF,. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci 2010; 1183: 38-57.
72. Iwata Y, Matsushita T, Horikawa M, et al,. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530-541.
73. Lafyatis R, Kissin E, York M, et al,. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60: 578-583.
74. Jordan S, Distler JH, Maurer B, et al,. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74: 1188-1194.
75. Goto M, Sato K, Murakami A, et al,. Development of a microchip-based bioassay system using cultured cells. Anal Chem 2005; 77: 2125-2131.